Product Description
Butoconazole is used to treat yeast infections of the vagina. Butoconazole nitrate is an antifungal prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of vulvovaginal candidiasis, which is an infection of the female vulva and vagina. Vulvovaginal candidiasis is a type of mucocutaneous candidiasis. Butoconazole is a member of the class of imidazoles that is 1H-imidazole in which the hydrogen attached to the nitrogen is substituted by a 4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl group. (Sourced from: https://medlineplus.gov/druginfo/meds/a682012.html)
Mechanisms of Action: CYP51A1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Vaginal,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Dominican Republic | Ecuador | Egypt | Hungary | India | Korea | Latvia | Luxembourg | Morocco | Netherlands | Pakistan | Peru | Poland | Romania | Russia | Serbia | Slovakia | Slovenia | Taiwan | United States
Approved Indications: None
Known Adverse Events: None
Company: Lumara Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Candidiasis, Vulvovaginal
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20132863 | P2 |
Active, not recruiting |
Candidiasis, Vulvovaginal |
2016-04-11 |